Conquering cardiovascular disease: progress and promise

Editorial

C Lenfant. JAMA. 1999.

. 1999 Dec 1;282(21):2068-70.

doi: 10.1001/jama.282.21.2068.

No abstract available

Comment on

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.
Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Furlan A, et al. JAMA. 1999 Dec 1;282(21):2003-11. doi: 10.1001/jama.282.21.2003. JAMA. 1999. PMID: 10591382 Clinical Trial.
Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women.
Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, Dyer AR, Liu K, Greenland P. Stamler J, et al. JAMA. 1999 Dec 1;282(21):2012-8. doi: 10.1001/jama.282.21.2012. JAMA. 1999. PMID: 10591383
Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Clark WM, et al. JAMA. 1999 Dec 1;282(21):2019-26. doi: 10.1001/jama.282.21.2019. JAMA. 1999. PMID: 10591384 Clinical Trial.